Published in Cancer Law Weekly, January 13th, 2007
This applicant is seeking authorization to market a generic version of thalidomide 200 mg tablets in the United States for the acute treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Celgene Corporation markets thalidomide under the brand name Thalomid and has approval to market as a treatment in combination with dexamethasone for newly diagnosed multiple myeloma, as well as for the acute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.